MAIA Biotechnology (MAIA) Q4 2024 earnings summary

Executive summary

• Clinical-stage biotech focused on telomere-targeting immunotherapies for cancer, with lead asset THIO in advanced clinical development for NSCLC and other indications.

• THIO-101 Phase 2 trial in NSCLC showed strong efficacy in third-line setting, with 38% ORR and 5.5 months median PFS, outperforming current treatments.

• Company plans to seek accelerated FDA approval for THIO in 2026 and initiate a pivotal Phase 3 trial in 2025.

• Multiple clinical and supply agreements in place, including with Regeneron and BeiGene, and robust patent portfolio.

• No commercial revenues to date; operations funded by equity offerings and private placements.

Financial highlights

• Net loss for 2024 was $23.3M, up from $19.8M in 2023, driven by warrant liability changes and ongoing R&D.

• Research and development expenses decreased 10% to $10.0M; general and administrative expenses decreased 23% to $6.9M.

• Cash as of December 31, 2024 was $9.6M, with working capital of $6.3M and total assets of $10.2M.

• Warrant liability increased to $2.7M, reflecting new issuances and reclassifications.

• No revenues recognized; accumulated deficit reached $87.2M.

Outlook and guidance

• Substantial doubt exists regarding ability to continue as a going concern without additional capital; further equity or debt financing will be required.

• Plans to seek accelerated approval for THIO in NSCLC in 2026, with Phase 3 trial (THIO-104) to begin in 2025.

• Expansion of THIO-101 to include additional arms and up to 148 patients; further trials in HCC, CRC, and SCLC planned for 2026.

• Ongoing efforts to broaden pipeline with next-generation telomere-targeting agents and additional cancer indications.